Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

[Detection of the JAK2 gene mutation in familial myeloproliferative neoplasm and its clinical significance].

Zhang YM, Hao LX, Wei Q, Wei YQ, Huang F, Zhang Y, Yin CX, Feng R.

Zhonghua Xue Ye Xue Za Zhi. 2012 Feb;33(2):103-7. Chinese.

PMID:
22730657
2.

[Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].

Chao HY, Fan Z, Zhang R, Shen YM, Chen W, Fei HR, Zhu ZL, Feng YF, Chen ZX, Xue YQ.

Zhonghua Zhong Liu Za Zhi. 2009 Jul;31(7):510-4. Chinese.

PMID:
19950698
3.

Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.

Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, Yoshida N, Ito M, Takahashi Y, Akita N, Sunami S, Ohtsuka Y, Asada Y, Fujisaki H, Kojima S.

Pediatr Blood Cancer. 2012 Sep;59(3):530-5. doi: 10.1002/pbc.23409. Epub 2011 Nov 21.

PMID:
22106054
5.

[A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].

Chao HY, Shen YM, Zhang R, Feng YF, Cen JN, Yao L, Shen HJ, Zhu ZL, Xue YQ.

Zhonghua Xue Ye Xue Za Zhi. 2009 May;30(5):321-5. Chinese.

PMID:
19799128
6.

Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.

Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, Palumbo G, Amendola A, Foà R, Larocca LM.

J Clin Oncol. 2007 Mar 20;25(9):1048-53.

PMID:
17369568
7.

[JAK2 V617F and exon 12 genetic variations in Korean patients with BCR/ABL1-negative myeloproliferative neoplasms].

Kim JT, Cho YG, Choi SI, Lee YJ, Kim HR, Jang SJ, Moon DS, Park YJ, Park G.

Korean J Lab Med. 2010 Dec;30(6):567-74. doi: 10.3343/kjlm.2010.30.6.567. Korean.

8.

Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.

Jaradat SA, Khasawneh R, Kamal N, Matalka I, Al-Bishtawi M, Al-Sweedan S, Ayesh MH.

Hematol Oncol Stem Cell Ther. 2015 Dec;8(4):160-6. doi: 10.1016/j.hemonc.2015.07.004. Epub 2015 Aug 1.

9.

Dkk3 levels in patients with myeloproliferative neoplasms.

Medinger M, Muesser P, Girsberger S, Skoda R, Tzankov A, Buser A, Passweg J, Tsakiris DΑ.

Thromb Res. 2014 Feb;133(2):218-21. doi: 10.1016/j.thromres.2013.11.003. Epub 2013 Nov 14.

PMID:
24309205
10.

Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.

Karkucak M, Yakut T, Ozkocaman V, Ozkalemkas F, Ali R, Bayram M, Gorukmez O, Ocakoglu G.

Mol Biol Rep. 2012 Sep;39(9):8663-7. doi: 10.1007/s11033-012-1721-x. Epub 2012 Jun 22.

PMID:
22722988
11.

Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.

Takata Y, Seki R, Kanajii T, Nohara M, Koteda S, Kawaguchi K, Nomura K, Nakamura T, Morishige S, Oku E, Osaki K, Hashiguchi E, Mouri F, Yoshimoto K, Nagafuji K, Okamura T.

Kurume Med J. 2014;60(3-4):89-97. Epub 2014 May 26.

12.

Detection of MPL exon10 mutations in 103 Chinese patients with JAK2V617F-negative myeloproliferative neoplasms.

Chen X, Qi X, Tan Y, Xu Z, Xu A, Zhang L, Wang H.

Blood Cells Mol Dis. 2011 Jun 15;47(1):67-71. doi: 10.1016/j.bcmd.2011.04.004. Epub 2011 May 8.

PMID:
21555228
13.

Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.

Bang SM, Lee JS, Ahn JY, Lee JH, Hyun MS, Kim BS, Park MR, Chi HS, Kim HY, Kim HJ, Lee MH, Kim H, Won JH, Yoon HJ, Oh DY, Nam EM, Bae SH, Kim BK; Korean MPN Working Party.

Thromb Haemost. 2009 Mar;101(3):547-51.

PMID:
19277418
14.

Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.

Yoo EH, Jang JH, Park KJ, Gwak GY, Kim HJ, Kim SH, Kim DK.

Int J Lab Hematol. 2011 Oct;33(5):471-6. doi: 10.1111/j.1751-553X.2011.01308.x. Epub 2011 Mar 24.

PMID:
21435189
15.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.

Leukemia. 2010 Jul;24(7):1302-9. doi: 10.1038/leu.2010.113. Epub 2010 May 27.

16.

[Detection and clinical significance of JAK2 V617F mutation in Chinese and Uyghur patients with chronic myeloproliferative in Xinjiang].

Zhang XY, Maimaitili Y, Li Y, An L, Mao M, Fu L, Baier M, Wang XM.

Zhonghua Xue Ye Xue Za Zhi. 2012 Dec;33(12):1020-3. Chinese.

PMID:
23363794
18.

[JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].

Wang JY, Ai XF, Xu JQ, Li QH, Xu ZF, Qin TJ, Zang Y, Xiao ZJ.

Zhonghua Xue Ye Xue Za Zhi. 2012 Sep;33(9):705-9. doi: 10.3760/cma.j.issn.0253-2727.2012.09.004. Chinese.

PMID:
23336221
19.

The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms.

Spasovski V, Tosic N, Nikcevic G, Stojiljkovic M, Zukic B, Radmilovic M, Karan-Djurasevic T, Srzentic S, Colovic M, Pavlovic S.

J Appl Genet. 2013 Feb;54(1):21-6. doi: 10.1007/s13353-012-0125-x. Epub 2012 Nov 28.

PMID:
23188718
20.

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].

Rajnai H, Bödör C, Reiniger L, Timár B, Csernus B, Szepesi A, Csomor J, Matolcsy A.

Orv Hetil. 2006 Nov 12;147(45):2175-9. Hungarian.

PMID:
17402211

Supplemental Content

Support Center